Clinical trials: Retroperitoneal Fibrosis

Retroperitoneal Fibrosis, Autoimmune Pancreatitis

Rituximab in IgG4-RD: A Phase 1-2 Trial

• Completed
• Age: 18 years and older
• Phase 1/2
• Injection or infusion
• Results posted

The primary objective of this study is to evaluate the safety and effectiveness of rituximab in IgG4-RD.

Conditions

Retroperitoneal Fibrosis, Autoimmune Pancreatitis, Sialadenitis, Pseudotumor

Trial name

NCT01584388

Testing

Rituximab

Volunteers

30 people

Sponsor

Massachusetts General Hospital